Adelaide-based biopharmaceutical company Bionomics’ came out of its share trading halt today, announcing results of key drug trials.

Bionomics is developing treatments for cancer, central nervous system disorders such as anxiety, depression and Alzheimer’s Disease.

The company’s portfolio of drug candidates range from being in early to advanced stages of clinical development.

Bionomics announced the results of the DISRUPTOR-1 trial of BNC105 in patients with metastatic renal cancer.

1 trial has been the first of its kind in testing the combination of an mTOR inhibitor with a vascular disrupting agent in renal cancer, with the prospect of adding a new dimension to the CEO & Managing Director.

“Significant progress has been made in validating BNC105 as an anti-cancer agent.

Through patient subgroup analysis and association of biomarkers to treatment benefit, the data from this trial shows us the best way forward to maximising the utility of BNC105 for renal cancer patients, as well as how to best employ the drug in other cancer types.

“DISRUPTOR-1 has produced a ground-breaking discovery of potential biomarkers that may allow pre-treatment selection of patients most likely to benefit from BNC105.”

Bionomic’s business strategy has been to partner with large pharmaceutical companies to get its drugs through the later stages of development and into the market.

“We are exploring partnership opportunities for BNC105 and expect to attract a depth of interest given the compelling data generated from this trial and the recent ovarian cancer trial data,” Dr Rathjen added.

Shares resumed trade at 74 cents this morning.

Analysts have recently upgraded their outlook for the share price.